Indoco Remedies Approves Sale Of Ophthalmic Business To Sunways

The pharmaceutical company announced that the transaction will be executed under SEBI-compliant frameworks, ensuring transparency and regulatory alignment. The divestment reflects Indoco Remedies’ intent to optimize its portfolio and strengthen its financial position.

Transaction Details

The ophthalmic business will be sold and transferred to Sunways under an ATB structure, valued at ₹1.10 billion. This agreement is expected to provide operational clarity and allow Indoco Remedies to channel resources into higher-growth segments.

Strategic Outlook

Analysts view the divestment as a positive step toward portfolio rationalization. By exiting the ophthalmic segment, Indoco Remedies can sharpen its focus on core therapeutic areas, enhance profitability, and pursue expansion in domestic and international markets.

Key highlights

• Deal valued at ₹1.10 billion
• Ophthalmic business to be transferred to Sunways
• Transaction structured through ATB mechanism
• Supports portfolio optimization and financial strengthening
• Focus shifts to core growth areas

Sources: Reuters, Economic Times, Business Standard